Cigarette smoking and clopidogrel interaction

Kristopher J. Swiger, Omair Yousuf, Kevin P. Bliden, Udaya S. Tantry, Paul A. Gurbel

Research output: Contribution to journalArticlepeer-review

Abstract

Dual antiplatelet therapy (DAPT) with aspirin and an adenosine diphosphate receptor antagonist is central to the modern management of acute coronary syndromes and percutaneous revascularization. The most widely used adenosine diphosphate receptor antagonist, clopidogrel therapy is limited by inter-individual variability in platelet inhibition. Recent data suggest a potential role of smoking in the metabolism of clopidogrel and high on-treatment platelet reactivity. Pharmacodynamic studies and post-hoc analyses of large clinical trials support a link between smoking status and the efficacy of clopidogrel therapy. The mechanism of the interaction between smoking status and clopidogrel efficacy remains unclear but may be mediated by cytochrome P450 (CYP)1A2. There is less evidence available on the influence of smoking status on platelet reactivity and clinical outcomes during prasugrel and ticagrelor therapy.

Original languageEnglish (US)
Article number361
JournalCurrent Cardiology Reports
Volume15
Issue number5
DOIs
StatePublished - May 2013

Keywords

  • Acute coronary syndrome
  • Adenosine diphosphate receptor antagonist
  • Clopidogrel
  • Dual antiplatelet therapy
  • High on-treatment platelet reactivity
  • Percutaneous coronary intervention
  • Percutaneous revascularization
  • Prasugrel
  • Smoking
  • Ticagrelor
  • Tobacco use

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint

Dive into the research topics of 'Cigarette smoking and clopidogrel interaction'. Together they form a unique fingerprint.

Cite this